Positive development in Nanexa’s patent litigation case
Nanexa AB today announced that the United States District Court for the District of Delaware in Nanexa AB v. VitriVax, Inc. C.A. No. 21-764 (JLH), today denied VitriVax’s motion to dismiss Nanexa’s complaint for patent infringement and denied as moot VitriVax’s motion to stay discovery. Furthermore, Nanexa’s motion to compel discovery was granted. Nanexa will continue to actively protect its valuable intellectual property rights related to its drug delivery system PharmaShell®.